Logo image of TCRX

TSCAN THERAPEUTICS INC (TCRX) Stock Fundamental Analysis

NASDAQ:TCRX - Nasdaq - US89854M1018 - Common Stock - Currency: USD

1.68  -0.1 (-5.62%)

After market: 1.69 +0.01 (+0.6%)

Fundamental Rating

2

Overall TCRX gets a fundamental rating of 2 out of 10. We evaluated TCRX against 558 industry peers in the Biotechnology industry. The financial health of TCRX is average, but there are quite some concerns on its profitability. TCRX is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year TCRX has reported negative net income.
In the past year TCRX has reported a negative cash flow from operations.
TCRX had negative earnings in each of the past 5 years.
TCRX had a negative operating cash flow in each of the past 5 years.
TCRX Yearly Net Income VS EBIT VS OCF VS FCFTCRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

Looking at the Return On Assets, with a value of -39.52%, TCRX is in line with its industry, outperforming 56.99% of the companies in the same industry.
Looking at the Return On Equity, with a value of -62.55%, TCRX is in line with its industry, outperforming 59.50% of the companies in the same industry.
Industry RankSector Rank
ROA -39.52%
ROE -62.55%
ROIC N/A
ROA(3y)-33.47%
ROA(5y)-35.77%
ROE(3y)-59.56%
ROE(5y)-72.17%
ROIC(3y)N/A
ROIC(5y)N/A
TCRX Yearly ROA, ROE, ROICTCRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for TCRX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TCRX Yearly Profit, Operating, Gross MarginsTCRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -1K -2K -3K -4K

More info and screens

4

2. Health

2.1 Basic Checks

TCRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
TCRX has more shares outstanding than it did 1 year ago.
The number of shares outstanding for TCRX has been increased compared to 5 years ago.
The debt/assets ratio for TCRX has been reduced compared to a year ago.
TCRX Yearly Shares OutstandingTCRX Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
TCRX Yearly Total Debt VS Total AssetsTCRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

Based on the Altman-Z score of -1.82, we must say that TCRX is in the distress zone and has some risk of bankruptcy.
TCRX has a Altman-Z score (-1.82) which is in line with its industry peers.
TCRX has a Debt/Equity ratio of 0.15. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.15, TCRX is doing worse than 68.64% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.15
Debt/FCF N/A
Altman-Z -1.82
ROIC/WACCN/A
WACC8.6%
TCRX Yearly LT Debt VS Equity VS FCFTCRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

TCRX has a Current Ratio of 8.55. This indicates that TCRX is financially healthy and has no problem in meeting its short term obligations.
TCRX has a better Current ratio (8.55) than 72.94% of its industry peers.
TCRX has a Quick Ratio of 8.55. This indicates that TCRX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 8.55, TCRX is in the better half of the industry, outperforming 72.94% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 8.55
Quick Ratio 8.55
TCRX Yearly Current Assets VS Current LiabilitesTCRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

4

3. Growth

3.1 Past

TCRX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 14.84%, which is quite good.
The Revenue for TCRX has decreased by -70.16% in the past year. This is quite bad
TCRX shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -34.76% yearly.
EPS 1Y (TTM)14.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.75%
Revenue 1Y (TTM)-70.16%
Revenue growth 3Y-34.76%
Revenue growth 5YN/A
Sales Q2Q%283.57%

3.2 Future

The Earnings Per Share is expected to grow by 12.15% on average over the next years. This is quite good.
The Revenue is expected to grow by 111.89% on average over the next years. This is a very strong growth
EPS Next Y0.62%
EPS Next 2Y2.72%
EPS Next 3Y2.73%
EPS Next 5Y12.15%
Revenue Next Year34.28%
Revenue Next 2Y23.73%
Revenue Next 3Y75.02%
Revenue Next 5Y111.89%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
TCRX Yearly Revenue VS EstimatesTCRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
TCRX Yearly EPS VS EstimatesTCRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -2 -4 -6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TCRX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TCRX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TCRX Price Earnings VS Forward Price EarningsTCRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TCRX Per share dataTCRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2 3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y2.72%
EPS Next 3Y2.73%

More info and screens

0

5. Dividend

5.1 Amount

TCRX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TSCAN THERAPEUTICS INC

NASDAQ:TCRX (6/5/2025, 8:12:08 PM)

After market: 1.69 +0.01 (+0.6%)

1.68

-0.1 (-5.62%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-06 2025-05-06/bmo
Earnings (Next)N/A N/A
Inst Owners85.13%
Inst Owner Change-3.59%
Ins Owners0.32%
Ins Owner Change0%
Market Cap95.07M
Analysts84.29
Price Target9.01 (436.31%)
Short Float %4.42%
Short Ratio3.8
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.71%
Min EPS beat(2)-7.46%
Max EPS beat(2)10.87%
EPS beat(4)3
Avg EPS beat(4)5.3%
Min EPS beat(4)-7.46%
Max EPS beat(4)14.81%
EPS beat(8)6
Avg EPS beat(8)13.93%
EPS beat(12)8
Avg EPS beat(12)8.76%
EPS beat(16)10
Avg EPS beat(16)-1.33%
Revenue beat(2)1
Avg Revenue beat(2)20.46%
Min Revenue beat(2)-51.71%
Max Revenue beat(2)92.64%
Revenue beat(4)1
Avg Revenue beat(4)-10.1%
Min Revenue beat(4)-78.27%
Max Revenue beat(4)92.64%
Revenue beat(8)2
Avg Revenue beat(8)-5.62%
Revenue beat(12)4
Avg Revenue beat(12)0.64%
Revenue beat(16)6
Avg Revenue beat(16)10.55%
PT rev (1m)0%
PT rev (3m)-27.26%
EPS NQ rev (1m)3.9%
EPS NQ rev (3m)1.54%
EPS NY rev (1m)5.04%
EPS NY rev (3m)4.02%
Revenue NQ rev (1m)20.23%
Revenue NQ rev (3m)-4.66%
Revenue NY rev (1m)14.63%
Revenue NY rev (3m)27.72%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 21.5
P/FCF N/A
P/OCF N/A
P/B 0.45
P/tB 0.45
EV/EBITDA N/A
EPS(TTM)-1.09
EYN/A
EPS(NY)-1.09
Fwd EYN/A
FCF(TTM)-2.19
FCFYN/A
OCF(TTM)-2.11
OCFYN/A
SpS0.08
BVpS3.71
TBVpS3.71
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -39.52%
ROE -62.55%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-33.47%
ROA(5y)-35.77%
ROE(3y)-59.56%
ROE(5y)-72.17%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0.15
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 131.71%
Cap/Sales 105.23%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.55
Quick Ratio 8.55
Altman-Z -1.82
F-Score4
WACC8.6%
ROIC/WACCN/A
Cap/Depr(3y)78.03%
Cap/Depr(5y)175.46%
Cap/Sales(3y)60.67%
Cap/Sales(5y)133.81%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)14.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.75%
EPS Next Y0.62%
EPS Next 2Y2.72%
EPS Next 3Y2.73%
EPS Next 5Y12.15%
Revenue 1Y (TTM)-70.16%
Revenue growth 3Y-34.76%
Revenue growth 5YN/A
Sales Q2Q%283.57%
Revenue Next Year34.28%
Revenue Next 2Y23.73%
Revenue Next 3Y75.02%
Revenue Next 5Y111.89%
EBIT growth 1Y-36.84%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-5.53%
EBIT Next 3Y19.08%
EBIT Next 5YN/A
FCF growth 1Y-66.14%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-70.27%
OCF growth 3YN/A
OCF growth 5YN/A